<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Immunosuppressants: rheumatic disease; Methotrexate: rheumatic disease; Azathioprine: rheumatic disease; Leflunomide; Ciclosporin: rheumatic disease; Cyclophosphamide: rheumatic disease; Lupus erythematosus: systemic; Polymyositis; Psoriatic arthritis" /><meta name="IX" content="Immunosuppressants: rheumatic disease; Methotrexate: rheumatic disease; Azathioprine: rheumatic disease; Leflunomide; Ciclosporin: rheumatic disease; Cyclophosphamide: rheumatic disease; Lupus erythematosus: systemic; Polymyositis; Psoriatic arthritis" /><title>Drugs affecting the immune response: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP6590-drugs-affecting-the-immune-response.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP6590-drugs-affecting-the-immune-response.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP6590-drugs-affecting-the-immune-response.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP6372-musculoskeletal-and-joint-diseases.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="PHP6373-drugs-used-in-rheumatic-diseases-and-gout.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm">10.1.3 Drugs that suppress the rheumatic disease process</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP6586-hydroxychloroquine-sulfate.htm" title="Previous: HYDROXYCHLOROQUINE SULFATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP6592-azathioprine.htm" title="Next: AZATHIOPRINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Drugs affecting the immune response</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Methotrexate</strong> is a disease-modifying antirheumatic drug suitable for moderate to severe rheumatoid arthritis. <strong>Azathioprine</strong>, <strong>ciclosporin</strong>, <strong>cyclophosphamide</strong>, <strong>leflunomide</strong>, and the <strong>cytokine modulators</strong> are considered more toxic and they are used in cases that have not responded to other disease-modifying drugs.</p> <p><strong>Methotrexate</strong> is usually given in an initial dose of 7.5 mg by mouth once a week, adjusted according to response to a maximum of 15 mg once a week (occasionally 20 mg once a week). Regular full blood counts (including differential white cell count and platelet count), renal and liver function tests are required. In patients who experience mucosal or gastro-intestinal side-effects with methotrexate, folic acid 5 mg every week [unlicensed indication], on a different day from the methotrexate, may help to reduce the frequency of such side-effects.</p> <p><strong>Azathioprine </strong>is usually given in a dose of up to 2.5 mg/kg daily in divided doses. Blood counts are needed to detect possible neutropenia or thrombocytopenia (usually resolved by reducing the dose). Nausea, vomiting, and diarrhoea may occur, usually starting early during the course of treatment, and may necessitate withdrawal of the drug; herpes zoster infection may also occur.</p> <p><strong>Leflunomide </strong>acts on the immune system as a disease-modifying antirheumatic drug. Its therapeutic effect starts after 4–6 weeks and improvement may continue for a further 4–6 months. Leflunomide, which is similar in efficacy to sulfasalazine and methotrexate, may be chosen when these drugs cannot be used. The active metabolite of leflunomide persists for a long period; active procedures to wash the drug out are required in case of serious adverse effects, or before starting treatment with another disease-modifying antirheumatic drug, or, in men or women, before conception. Side-effects of leflunomide include bone-marrow toxicity; its immunosuppressive effects increase the risk of infection and malignancy. </p> <p><strong>Ciclosporin</strong> is licensed for severe active rheumatoid arthritis when conventional second-line therapy is inappropriate or ineffective. There is some evidence that ciclosporin may retard the rate of erosive progression and improve symptom control in those who respond only partially to methotrexate.</p> <p id="PHP6591"><strong>Cyclophosphamide</strong> (<a title=" Alkylating drugs" href="PHP5236-alkylating-drugs.htm">section 8.1.1</a>) may be used at a dose of 1 to 1.5 mg/kg daily by mouth for rheumatoid arthritis with severe systemic manifestations [unlicensed indication]; it is toxic and regular blood counts (including platelet counts) should be carried out. Cyclophosphamide can also be given intravenously in a dose of 0.5 to 1 g (with prophylactic mesna) for <em>severe systemic rheumatoid arthritis</em> and for other connective tissue diseases (especially with active vasculitis), repeated initially at fortnightly then at monthly intervals (according to clinical response and haematological monitoring).</p> <p>Drugs that affect the immune response are also used in the management of severe cases of <em>systemic lupus erythematosus </em>and other connective tissue disorders. They are often given in conjunction with corticosteroids for patients with severe or progressive renal disease. They may be used in cases of <em>polymyositis </em>that are resistant to corticosteroids. They are used for their corticosteroid-sparing effect in patients whose corticosteroid requirements are excessive. <strong>Azathioprine </strong>is usually used.</p> <p>In the specialist management of psoriatic arthritis affecting peripheral joints, leflunomide, methotrexate, or azathioprine [unlicensed indication] may be used.</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP6592-azathioprine"><a href="PHP6592-azathioprine.htm" title="AZATHIOPRINE">AZATHIOPRINE</a></li><li id="_PHP6594-ciclosporin"><a href="PHP6594-ciclosporin.htm" title="CICLOSPORIN">CICLOSPORIN</a></li><li id="_PHP6596-leflunomide"><a href="PHP6596-leflunomide.htm" title="LEFLUNOMIDE">LEFLUNOMIDE</a></li><li id="_PHP6599-methotrexate"><a href="PHP6599-methotrexate.htm" title="METHOTREXATE">METHOTREXATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP6586-hydroxychloroquine-sulfate.htm">Previous: HYDROXYCHLOROQUINE SULFATE</a> | <a class="top" href="PHP6590-drugs-affecting-the-immune-response.htm#">Top</a> | <a accesskey="]" href="PHP6592-azathioprine.htm">Next: AZATHIOPRINE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>